The expanded cast of health companies enables unprecedented predictive and preventive care delivery that is convenient, seamlessly connected, and coordinated across geographic boundaries. Meanwhile consumers have access to a marketplace with transparency around price, quality, outcomes, and value. Main and Slywotzky predict this new market will lower costs by 40 percent, produce 10 more good years of living, and improve consumer experience by 300 percent. With more than a trillion dollars at stake, this transformation represents the greatest value migration in history. This paper shares how traditional players and new entrants can do more than participate in this value shift but lead it through innovative business models and partnerships.
UNLOCKING THE INCUMBENT’S DILEMMA
When an industry faces a transition like the one occurring in healthcare, only the strongest, quick-to-react incumbents survive, in the likes of IBM, Apple, and Amazon. What, then, will it take for healthcare incumbents to play a meaningful role in Health Market 2.0? Unlocking the incumbent’s dilemma is no easy task. The rate of failure far exceeds that of success—and in most recounts of industry transformation the incumbents end up as a footnote. Through in-depth leadership discussions with incumbents and innovators, and careful study of non-healthcare success stories, we found the following six insights to unlocking the incumbent’s dilemma:
1. Change your frame of reference. Health Market 2.0 combines health and wellness, includes retail, and shifts the market from being supply-led to demand-led. It also breaks the “healthcare is local” paradigm.
2. Be aware of your place on the value ladder. Thinking you are best-in-class and an industry standard when you are about to be commoditized by a better value alternative is a peril within markets that are undergoing transformational change.
3. Know it is not a level playing field. Many of the new players in Health Market 2.0 are competing at silicon speeds, in a global marketplace, using ecosystem thinking, and constantly innovating. Not surprisingly, they are favored by capital markets. Partnering provides access to these advantages.
4. Run skip generation plays. Continued incremental improvements on the current business model are not sufficient. Incumbents need to execute leapfrog strategies with entirely new capabilities (e.g. big data, passive monitoring, and retail pharmacy integration) and novel partnerships to thrive in Health Market 2.0.
5. Don’t go it alone. Bridging health and wellness, becoming a consumer company, redefining personalization, deploying big data, developing complex adaptive workflows, and leveraging passive monitoring to prevent most acute events—these are massive but critical changes. Partnering will accelerate your path and is likely a necessity.
6. Leadership is the scarcest commodity. While it feels less risky to focus on current Health Market 1.0 business model innovations and improving the “today return picture”, history tells us unmistakably that even the very best run incumbents hemorrhage value as markets transform. Leadership, not refinement, is what’s needed to survive.